News Details

( 05/01/2018 15:06)
Lupin unveils generic Ancobon capsules in US

Leading pharma major Lupin has said that it has launched Flucytosine capsules, used to treat serious infections, in the American market.

“The company has launched its generic product in the strengths of 250 mg and 500 mg after having received approval from the US Food and Drug Administration (USFDA),” Lupin said in a filing to the Bombay Stock Exchange.

The Mumbai-based company's product is the generic version of Valeant Pharmaceuticals International Inc's Ancobon tablets. The drug is indicated for the treatment of serious infections.

As per the latest IMS sales data, Flucytosine capsules have annual sales of around USD 48 million in the US.

Meanwhile, shares of the company were trading at Rs 899.80 apiece, up 2.54 per cent from the previous close at 15:12 hrs on BSE.

ATTENTION INVESTORS 1 : "No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case | 2 : "Prevent Unauthorized Transactions in your demat / trading account --> Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors. | 3 : KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.

SEBI Regn. NSE: INB231280430 I F&O: INF231280430 I BSE: INB011280436 I NSE CD: INE231280430 I MCX-SX: INE261280430

Copyright © 2017 Rikhav Securities Ltd. All rights reserved

Designed , Developed & Content Powered by DION